Classes
DEA Class; Rx
Common Brand Names; Chantix
- Smoking Cessation Aids
varenicline intranasal (Rx)
- Classes: Cholinergic Agonists
Description
Nicotinic acetylcholine receptor agonist
Oral formulation used to promote smoking cessation; intranasal formulation used for dry eye disease
Monitor closely for emerging or worsening suicidal thoughts/behavior, depression, or other changes in mood or behavior
Indications
Indicated for use as an adjunct to psychosocial interventions for tobacco cessation (smoking cessation).
Contraindications
Documented hypersensitivity or skin reactions to drug or components of formulation
Nonsmokers
Adverse Effects
- Nausea (15-40%; dose related)
- Abnormal dreams
- Headache
- Insomnia
- Appetite changes
- Chest pain
- Constipation
- Dry mouth
- Dyspepsia
- Dyspnea
- Flatulence
- Gastroesophageal reflux disease (GERD)
- Fatigue or lethargy
- Pruritus
- Rash
- Somnolence
- Rhinorrhea
- Vomiting
- Upper respiratory tract disorder
- Abnormal liver function tests
- Anemia
- Anxiety
- Arrhythmia
- Arthralgia
- Depression
- Diarrhea
- Dizziness
- Epistaxis
- Hypertension
- Myocardial infarction (MI)
- Polyuria
- Respiratory disorder
Warnings
May cause nausea; reduce dose if nausea occurs
Somnambulism reported, including cases describing harmful behavior to self, others, or property; instruct patients to discontinue varenicline and notify their healthcare professional
Seizures reported; some patients had no history of seizures, whereas others had a history of seizure disorder that was remote or well-controlled; in most cases, the seizure occurred within the first month of therapy; use with caution in patients with history of seizures or with other factors that might lower seizure threshold
May cause CNS depression; use caution when performing tasks requiring mental alertness, such as, operating heavy machinery or driving
Hypersensitivity reactions reported, including angioedema
Rare but serious skin reactions reported, including Stevens-Johnson Syndrome and erythema multiforme
Pregnancy and Lactation
Available data have not suggested increased risk for major birth defects following exposure to varenicline in pregnancy, compared with women who smoke
Because there are no data on presence of varenicline in human milk and effects on breastfed infant, breastfeeding women should monitor their infant for seizures and excessive vomiting, which are adverse reactions that have occurred in adults that may be clinically relevant in breastfeeding infants
Maximum Dosage
2 mg per day PO; 0.12 mg (4 sprays) intranasally per day.
2 mg per day PO; 0.12 mg (4 sprays) intranasally per day.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Varenicline
tablet
- 0.5mg
- 1mg
intranasal solution
- 1 actuation delivers 0.03mg/0.05mL